Exubera Success May Hinge on Usability
Part 2 of 2. To read part one, click here.
At the recent annual scientific meeting of the American Diabetes Association, the Pfizer (PFE) booth was jam-packed with doctors, nurses, academics and analysts angling for a firsthand look at the Exubera insulin inhaler.
"Change the diabetes experience," said one video display as a platoon of Pfizer representatives showed onlookers how to use the inhaler. To be sure, the New York-based drug giant hopes to vastly alter the way diabetics get their insulin by giving them the first option to injections to come on the market.
However, questions remain about just how easy the device is to use and whether a large number of insulin users will in fact make the switch."We still believe the device is a bit large, but [we] found it easy to use," Catherine Arnold of Credit Suisse wrote in research report after the June ADA meeting. She went on to say, though, that the "size and maintenance requirements of the device largely offset the convenience offered by inhaled administration." The inhaler itself was developed by Nektar Therapeutics (NKTR). Both that company and Pfizer are counting on Exubera to attract new patients and perhaps convert existing diabetics to what they say is an easier way to control blood-sugar levels, even if the drug costs more than injectable insulin. Arnold for one is concerned that it will take Pfizer 12 to 18 months to educate patients and doctors about safety and device-management issues. She's neutral on Pfizer, and she doesn't cover Nektar. She doesn't own shares of the companies, but her firm says it does or seeks to do business with firms mentioned in its research reports. "Most clinicians we spoke with indicated there is substantial patient interest in Exubera," Barbara Ryan of Deutsche Bank Securities said in a post-convention review. "They felt the device was certainly less than ideal, but it was generally viewed as easy to use."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV